BACKGROUND: Our previous report showed an association between age and outcome in gefitinib-treated female patients with non-small cell lung cancer (NSCLC). Only limited numbers of molecular studies have been performed with respect to the presence of epidermal growth factor receptor (EGFR) mutations according to age. This retrospective study was performed to evaluate a possible association between age at the time diagnosis and the presence of EGFR mutations in female patients with NSCLC. METHODS: Tumor specimens were collected retrospectively from paraffin blocks of 98 female patients with primary NSCLC who underwent surgical resection between January 1992 and December 2002 at the Korea Cancer Center Hospital. To detect EGFR mutations, a Scorpion Amplified Refractory Mutation System was used. RESULTS: Most of the study population comprised never smokers (84%) and patients with adenocarcinoma (82%). The age at the time of diagnosis ranged from 34 to 74 years (median, 57 years). When the median age was used as a cutoff value, older patients were more likely to have EGFR mutations than younger patients (70 versus 39%; p = 0.004). After controlling for the effects of histology, smoking history, and stage, age remained a significant predictor for EGFR mutations (odds ratio, 4.03; 95% confidence interval, 1.61-10.09; p = 0.003). CONCLUSIONS: Our data suggest that age at the time of diagnosis in female patients with NSCLC may be associated with the frequency of EGFR mutations, a strong indicator for favorable outcomes.
BACKGROUND: Our previous report showed an association between age and outcome in gefitinib-treated female patients with non-small cell lung cancer (NSCLC). Only limited numbers of molecular studies have been performed with respect to the presence of epidermal growth factor receptor (EGFR) mutations according to age. This retrospective study was performed to evaluate a possible association between age at the time diagnosis and the presence of EGFR mutations in female patients with NSCLC. METHODS: Tumor specimens were collected retrospectively from paraffin blocks of 98 female patients with primary NSCLC who underwent surgical resection between January 1992 and December 2002 at the Korea Cancer Center Hospital. To detect EGFR mutations, a Scorpion Amplified Refractory Mutation System was used. RESULTS: Most of the study population comprised never smokers (84%) and patients with adenocarcinoma (82%). The age at the time of diagnosis ranged from 34 to 74 years (median, 57 years). When the median age was used as a cutoff value, older patients were more likely to have EGFR mutations than younger patients (70 versus 39%; p = 0.004). After controlling for the effects of histology, smoking history, and stage, age remained a significant predictor for EGFR mutations (odds ratio, 4.03; 95% confidence interval, 1.61-10.09; p = 0.003). CONCLUSIONS: Our data suggest that age at the time of diagnosis in female patients with NSCLC may be associated with the frequency of EGFR mutations, a strong indicator for favorable outcomes.
Authors: Evgeny N Imyanitov; Irina A Demidova; Marat G Gordiev; Maxim L Filipenko; Tatyana V Kekeyeva; Yuri K Moliaka; Polina A Gervas; Valeriy B Kozhemyako; Dmitriy I Vodolazhskiy; Liubov A Sergeyeva; Dinara U Fattakhova; Aglaya G Iyevleva; Natalia V Mitiushkina; Ekatherina Sh Kuligina; Alexey A Barinov; Meriiam S Mommaeva; Svetlana N Aleksakhina; Ilya V Tsimafeyeu; Sergey A Tjulandin Journal: Mol Diagn Ther Date: 2016-08 Impact factor: 4.074
Authors: Chenguang Li; Rong Fang; Yihua Sun; Xiangkun Han; Fei Li; Bin Gao; A John Iafrate; Xin-Yuan Liu; William Pao; Haiquan Chen; Hongbin Ji Journal: PLoS One Date: 2011-11-30 Impact factor: 3.240
Authors: Sang Yun Ha; So-Jung Choi; Jong Ho Cho; Hye Joo Choi; Jinseon Lee; Kyungsoo Jung; Darry Irwin; Xiao Liu; Maruja E Lira; Mao Mao; Hong Kwan Kim; Yong Soo Choi; Young Mog Shim; Woong Yang Park; Yoon-La Choi; Jhingook Kim Journal: Oncotarget Date: 2015-03-10
Authors: Audrey Vallee; Christine Sagan; Anne-Gaelle Le Loupp; Kalyane Bach; Thomas Dejoie; Marc G Denis Journal: Int J Oncol Date: 2013-08-07 Impact factor: 5.650